Logo

Genmab Signs an Agreement with Tempus to Develop Novel Targets and Biomarkers for Cancer Indications

Share this

Genmab Signs an Agreement with Tempus to Develop Novel Targets and Biomarkers for Cancer Indications

Shots:

  • Tempus to receive milestones and royalties and has an option to fund part of product development programs in return of high royalty payments. Genmab and Tempus will jointly develop novel drugs and biomarkers for the novel concept identified by Genmab
  • The collaboration follows the expansion of their existing service agreement and will utilize Tempus’ technology platform and sequencing capabilities to discover cancer biomarkers. Genmab will lead all development and commercial activities
  • Tempus is focused on developing precision medicine by gathering and analyzing clinical and molecular data at scale and has built the world’s largest library of clinical and molecular data for improving the lives of cancer patients

Click here to­ read full press release/ article | Ref: Genmab | Image: Genmab


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions